| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17405 R72983 |
Madley-Dowd_SE (Carbamazepine) (Controls exposed to LTG) (Mixed indications), 2024 | Intellectual disability (intelligence quotient below 70) - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes Partial overlapping |
1.17 [0.82;1.68] excluded (control group) |
64/2,427 60/5,035 | 124 | 2,427 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17406 R72987 |
Madley-Dowd_SE (Carbamazepine) (Controls unexposed, general pop) (Mixed indications), 2024 | Intellectual disability (intelligence quotient below 70) - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 1.28 [0.98;1.68] | 64/2,427 24,323/2,651,210 | 24,387 | 2,427 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17407 R72991 |
Madley-Dowd_SE (Carbamazepine) (Controls unexposed, sibling) (Mixed indications), 2024 | Intellectual disability (intelligence quotient below 70) - ICD-8/9/10 codes - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | sibling excluded | Adjustment: Yes Partial overlapping |
0.74 [0.35;1.57] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17280 R72326 |
Madley-Dowd_UK (Carbamazepine) (Controls exposed to LTG) (Mixed indications), 2024 | Intellectual disability - ICD10 codes - Median CBZ 9.17 (5.31-12.54) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
1.06 [0.27;4.16] excluded (control group) |
-/603 -/939 | - | 603 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17264 R72274 |
Madley-Dowd_UK (Carbamazepine) (Controls unexposed, general pop) (Mixed indications), 2024 | Intellectual disability - ICD10 codes - Median CBZ 9.17 (5.31-12.54) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.67 [0.58;4.85] | -/603 1,119/514,066 | - | 603 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17272 R72302 |
Madley-Dowd_UK (Carbamazepine) (Controls unexposed, sibling) (Mixed indications), 2024 | Intellectual disability - ICD10 codes - Median CBZ 9.17 (5.31-12.54) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | sibling excluded | Adjustment: Yes |
8.21 [3.14;21.44] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12749 R48104 |
Bjørk (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) - Median follow up carbamazepine 10.5 (6.4-16.6) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
3.28 [1.99;5.41] C excluded (control group) |
36/3,256 27/7,950 | 63 | 3,256 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12748 R48101 |
Bjørk (Carbamazepine) (Controls unexposed NOS) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) - Median follow up carbamazepine 10.5 (6.4-16.6) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
2.01 [1.45;2.79] excluded (control group) |
36/3,256 16,384/4,463,879 | 16,420 | 3,256 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12747 R48098 |
Bjørk (Carbamazepine) (Controls unexposed, sick) (Mixed indications), 2022 | Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) - Median follow up carbamazepine 10.5 (6.4-16.6) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 1.73 [1.20;2.50] C | 36/3,256 139/21,634 | 175 | 3,256 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9732 R34654 |
Meador (Carbamazepine), 2013 | IQ <70 (DAS) (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: Yes | 3.71 [0.15;92.65] C | 1/61 0/74 | 1 | 61 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9738 R34694 |
Titze (Carbamazepine) (Controls unexposed, disease free), 2008 | Learning disability (IQ<70) (German versions of the revised Wechsler Intelligence Scales for children and for adults) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
13.86 [0.24;809.27] C excluded (control group) |
0/4 0/49 | 0 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9739 R34695 |
Titze (Carbamazepine) (Controls unexposed, sick), 2008 | Learning disability (IQ<70) (German versions of the revised Wechsler Intelligence Scales for children and for adults) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.10 [0.04;33.38] C | 0/4 1/13 | 1 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9747 R34799 |
Viinikainen (Carbamazepine) b, 2006 | Full Scale IQ (FIQ) < 2SD (Wechsler Intelligence Scale for Children (WISC-III)) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.00 [0.02;54.47] C | 0/13 0/13 | 0 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9748 R34809 |
Vinten (Carbamazepine), 2005 | IQ score <69 (Wechsler Intelligence Scale for Children (WISC-III)) (Aged between 6 and 16 years) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 1.03 [0.28;3.83] C | 4/52 6/80 | 10 | 52 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9720 R34597 |
Gaily (Carbamazepine) (Controls unexposed, disease free), 2004 | Mental retardation (Verbal and nonverbal IQ <70) | 2nd and/or 3rd trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
0.54 [0.06;5.29] C excluded (control group) |
1/86 3/141 | 4 | 86 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9721 R34601 |
Gaily (Carbamazepine) (Controls unexposed, sick), 2004 | Mental retardation (Verbal and nonverbal IQ <70) | 2nd and/or 3rd trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.25 [0.02;2.87] C | 1/86 2/45 | 3 | 86 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 8 studies | 1.40 [1.14;1.73] | 24,577 | 6,502 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine) (Controls unexposed, general pop) (Mixed indications; 2: Carbamazepine) (Controls unexposed, general pop) (Mixed indications; 3: Carbamazepine) (Controls unexposed, sick) (Mixed indications; 4: Carbamazepine; 5: Carbamazepine) (Controls unexposed, sick; 6: Carbamazepine) ; 7: Carbamazepine; 8: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.6517 (by Egger's regression)
slope=0.3794 (0.1226); intercept=-0.1935 (0.4075); t=0.4749; p=0.6517
excluded 9720, 9738, 12749, 12748, 17405, 17407, 17280, 17272